Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

A Case of Eosinophilic Fasciitis Presenting with Pansclerotic Morphea

Julia K. Munchel, MD, & William E. Monaco, MD  |  Issue: May 2019  |  May 17, 2019

Eosinophilic fasciitis can be distinguished from scleroderma largely by a lack of Raynaud’s phenomenon, normal nailfold capillaroscopy & the absence of visceral organ involvement.

Discussion

Currently in the literature, several case reports describe patients with atypical presentations of eosinophilic fasciitis involving the face and hands, but we believe our case is the first describing a patient presenting with diffuse, pansclerotic, scleroderma-like skin involvement.5

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Acknowledging that a wide diversity of location and degree of skin involvement beyond the typically indurated extremities exists is especially relevant considering the suggestion that joint contractures are the main morbidity associated with eosinophilic fasciitis. Contractures occur in 76% of untreated patients.2,6

Our patient was not referred to a rheuma­tologist until about one year into her illness and had a diagnostic delay of 23 months. A delay of just six months has been significantly associated with a 14.7 times greater risk of poor treatment response.2 Also, both trunk involvement and concurrent morphea are associated with more severe manifestations of disease. Patients suffering from morphea have a 1.9-fold greater risk of corticosteroid resistance and are three times as likely to require additional immuno­suppressive medications.2

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Even further striking is the suggestion that the presence of morphea alone may represent a subset of eosinophilic fasciitis patients who are more likely to suffer from residual damage regardless of a diagnostic delay.6 This underlines the importance of having a high index of suspicion for eosinophilic fasciitis in patients presenting with morphea and obtaining full-thickness biopsies when eosinophilic fasciitis is on the differential diagnosis.

Conclusion

Eosinophilic fasciitis is a relatively rare diagnosis with a presentation that is increasingly recognized to be diverse, but as of yet has no codified diagnostic criteria.3 This combination makes its diagnosis particularly challenging, especially in the face of a presentation—such as in our patient—of an unusual degree of skin involvement, which makes it easy to mistake eosinophilic fasciitis for an alternative scleroderma mimic, like scleromyxedema.2  


Julia Munchel, MDJulia Munchel, MD, is a third-year postgraduate, studying internal medicine at Dartmouth-Hitchcock Medical Center, Lebanon, N.H.

William Monaco, MDWilliam Monaco, MD, works as a rheumatologist at Maine General Medical Center in Augusta.

References

  1. Lakhanpal S, Ginsburg WW, Michet CJ, et al. Eosinophilic fasciitis: Clinical spectrum and therapeutic response in 52 cases. Semin Arthritis Rheum. 1988 May;17(4):221–231.
  2. Mazori DR, Femia AN, Vleugels RA. Eosinophilic fasciitis: An updated review on diagnosis and treatment. Curr Rheumatol Rep. 2017 Nov 4;19(12):74.
  3. Bischoff L, Derk CT. Eosinophilic fasciitis: Demographics, disease pattern and response to treatment: Report of 12 cases and review of the literature. Int J Dermatol. 2008 Jan;
    47(1):29–35.
  4. Morgan ND, Hummers LK. Scleroderma mimickers. Curr Treatm Opt Rheumatol. 2016 Mar;2(1):69–84.
  5. Pardos-Gea J. Positive prayer sign in eosinophilic fasciitis. Rheumatology (Oxford). 2017 Apr 1;56(4):628.
  6. Suzuki S, Noda K, Ohira Y, et al. Finger stiffness or edema as presenting symptoms of eosinophilic fasciitis. Rheumatol Int. 2015 Oct;35(10):1769–1772.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsSystemic Sclerosis Tagged with:eosinophilic fasciitispansclerotic morphea

Related Articles
    Kamolrat/SHUTTERSTOCK.COM

    Eosinophilia: A Diagnostic Evaluation Guide for Rheumatologists

    June 15, 2015

    Clinical Vignette A 45-year-old woman with long-standing asthma and chronic sinusitis has new-onset peripheral neuropathy, arthralgias, fatigue, progressive dyspnea and a nonproductive cough. She has never smoked and has no environmental exposures. Her medications include an albuterol metered-dose inhaler (which she uses daily); an inhaled corticosteroid, montelukast; and ibuprofen (which she takes occasionally). She is…

    Study Probes New Gene Therapy for Severe, Localized Scleroderma (Morphea)

    August 16, 2019

    In September 2018, the U.S. Food & Drug Administration (FDA) granted fast-track status to FCX‑013, a gene therapy product developed to treat moderate to severe localized scleroderma (morphea). Previously, the treatment received an orphan drug designation for localized scleroderma, as well as a rare pediatric disease designation. Phase 1 and 2 studies will assess safety…

    Figures 1 & 2: On exam, the patient had thickening of the skin on her extremities.

    Dermatology Symptoms Point to Connective Tissue Disorder

    May 15, 2015

    The Case A 68-year-old woman with a past medical history of Charcot-Marie-Tooth presents with thickening of the skin on her trunk and extremities, which she has had for the past seven months (see Figures 1 and 2). Her symptoms first began with swelling of her bilateral upper and lower extremities. She is now having difficulty…

    Fellows’ Forum Case Report: Palmar Fasciitis & Polyarthritis Syndrome

    November 16, 2015

    Case report: A 78-year-old Caucasian female presented to our outpatient rheumatology clinic with pain in her bilateral shoulders, hands and knees that began suddenly one month earlier. She admitted to stiffness in her hands lasting several hours, and expressed an inability to extend her fingers. She denied fever, rashes, jaw claudication, headache or visual changes….

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences